Portage Biotech (PRTG) reported late Thursday "encouraging" efficacy data in a murine mesothelioma model with PORT-7 given as a single agent or in combination with anti-PD-1 antibody.
The data showed both single agent activity, and more than 90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma, it said.
"This is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor," Portage said, adding that it's making preparations to start a first-in-human trial.
The shares more than doubled in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.